Image Place holder

Lewis Glass, MD

Specialty: Dermatology
Sub Specialty: Dermatopathology
Program: Cutaneous Oncology

Overview

Cancer Focus: Cutaneous Lymphoma (CTCL)

Dr. Frank Glass is a specialist in dermatology and dermatopathology in the Department of Cutaneous Oncology at Moffitt Cancer Center.  He is a professor of dermatology and cutaneous surgery and a professor of pathology and cell biology at the University of South Florida College of Medicine. In addition, he directs the dermatopathology fellowship program for USF, Moffitt and the James A. Haley Veterans Hospital in Tampa. Dr. Glass’s research and clinical interests include melanoma, cutaneous lymphoma, and non-melanoma skin cancer. A graduate of Louisiana State University School of Medicine, Dr. Glass served a residency in dermatology at the University of Southern California and completed a fellowship in dermatopathology at the Medical University of South Carolina. A frequent guest lecturer, Dr. Glass is widely published in professional journals and serves as a journal reviewer for the Journal of the American Academy of Dermatology, American Journal of Dermatopathology and Dermatologic Surgery. Dr. Glass is a member of numerous professional societies, including the American Academy of Dermatology, American Society of Dermatopathology, International Society of Dermatopathology and Florida West Coast Dermatologic Society, of which he is the treasurer.  He received the 2004 Distinguished Service Award from the Florida Society of Dermatology and Dermatologic Surgery.  


Education & Training

Board Certification:

  • Dermatology - Dermatopathology

Fellowship:

  • Medical University of South Carolina - Dermatopathology

Residency:

  • University of South California - Dermatology

Medical School:

  • Louisiana State University, New Orleans - MD
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Horna P, Shao H, Idrees A, Glass LF, Torres-Cabala CA. Indeterminate dendritic cell neoplasm of the skin: A 2-case report and review of the literature. J Cutan Pathol. 2017 Nov.44(11):958-963. Pubmedid: 28880462.
  • Horna P, Kurant D, Sokol L, Sotomayor EM, Moscinski L, Glass LF. Flow cytometric identification of immunophenotypically aberrant T-cell clusters on skin shave biopsy specimens from patients with mycosis fungoides. Am J Clin Pathol. 2015 Jun.143(6):785-796. Pubmedid: 25972320.
  • Sondak VK, Glass LF, Geller AC. Risk-stratified screening for detection of melanoma. Jama. 2015 Feb.313(6):616-617. Pubmedid: 25668265.
  • Braue J, Hagele T, Yacoub AT, Mannivanan S, Sokol L, Glass F, Greene JN. A case of rupioid syphilis masquerading as aggressive cutaneous lymphoma. Mediterr J Hematol Infect Dis. 2015 Apr.7(1):e2015026. Pubmedid: 25960854. Pmcid: PMC4418386.
  • Horna P, Deaver DM, Qin D, Moscinski LC, Sotomayor EM, Glass LF, Sokol L. Quantitative flow cytometric identification of aberrant T cell clusters in erythrodermic cutaneous T cell lymphoma. Implications for staging and prognosis. J Clin Pathol. 2014 May.67(5):431-436. Pubmedid: 24319102.
  • Zager JS, Messina JL, Glass LF, Sondak VK. Unanswered questions in the management of stage I-III Merkel cell carcinoma. J Natl Compr Canc Ne. 2014 Mar.12(3):425-431. Pubmedid: 24616546.
  • Bichakjian CK, Olencki T, Alam M, Andersen JS, Berg D, Bowen GM, Cheney RT, Daniels GA, Glass LF, Grekin RC, Grossman K, Ho AL, Lewis KD, Lydiatt DD, Morrison WH, Nehal KS, Nelson KC, Nghiem P, Perlis CS, Shaha AR, Thorstad WL, Tuli M, Urist MM, Wang TS, Werchniak AE, Wong SL, Zic JA, Hoffmann KG, McMillian NR, Ho M. Merkel cell carcinoma, version 1.2014. J Natl Compr Canc Ne. 2014 Mar.12(3):410-424. Pubmedid: 24616545. Pmcid: PMC9441108.
  • Deaver D, Cauthen A, Cohen G, Sokol L, Glass F. Excimer laser in the treatment of mycosis fungoides. J Am Acad Dermatol. 2014 Jun.70(6):1058-1060. Pubmedid: 24775402.
  • Bichakjian CK, Olencki T, Alam M, Andersen JS, Berg D, Bowen GM, Cheney RT, Daniels GA, Glass LF, Grekin RC, Grossman K, Ho AL, Lewis KD, Lydiatt DD, Morrison WH, Nehal KS, Nelson KC, Nghiem P, Perlis CS, Shaha AR, Thorstad WL, Tuli M, Urist MM, Wang TS, Werchniak AE, Wong SL, Zic JA, McMillian N, Hoffman K, Ho M. Dermatofibrosarcoma protuberans, version 1.2014. J Natl Compr Canc Ne. 2014 Jun.12(6):863-868. Pubmedid: 24925197.
  • Thareja S, Zager JS, Sadhwani D, Thareja S, Chen R, Marzban S, Jukic DM, Glass LF, Messina J. Analysis of tumor mitotic rate in thin metastatic melanomas compared with thin melanomas without metastasis using both the hematoxylin and eosin and anti-phosphohistone 3 IHC stain. Am J Dermatopathxxx. 2014 Jan.36(1):64-67. Pubmedid: 24451214. Pmcid: PMC5764097.
  • Horna P, Hamill JR, Sokol L, Glass LF. Primary cutaneous plasmablastic lymphoma in an immunocompetent patient. J Am Acad Dermatol. 2013 Nov.69(5):e274-e276. Pubmedid: 24124865.
  • Held L, Eigentler TK, Metzler G, Leiter U, Messina JL, Glass LF, Garbe C, Bauer J. Proliferative activity, chromosomal aberrations, and tumor-specific mutations in the differential diagnosis between blue nevi and melanoma. Am J Pathol. 2013 Mar.182(3):640-645. Pubmedid: 23261261.
  • McNab PM, Quigley BC, Glass LF, Jukic DM. Composite hemangioendothelioma and its classification as a low-grade malignancy. Am J Dermatopathxxx. 2013 Jun.35(4):517-522. Pubmedid: 23694827.
  • Miller SJ, Alam M, Andersen JS, Berg D, Bichakjian CK, Bowen GM, Cheney RT, Glass LF, Grekin RC, Ho AL, Kessinger A, Liegeois N, Lydiatt DD, Michalski J, Morrison WH, Nehal KS, Nelson KC, Nghiem P, Olencki T, Perlis CS, Shaha AR, Tuli M, Urist MM, Wang LC, Zic JA. Dermatofibrosarcoma protuberans. J Natl Compr Canc Ne. 2012 Mar.10(3):312-318. Pubmedid: 22393193.
  • Sokol L, Naghashpour M, Glass LF. Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management. Cancer Control. 2012 Jul.19(3):236-244. Pubmedid: 22710899.
  • Rollison DE, Iannacone MR, Messina JL, Glass LF, Giuliano AR, Roetzheim RG, Cherpelis BS, Fenske NA, Jonathan KA, Sondak VK. Case-control study of smoking and non-melanoma skin cancer. Cancer Causes Control. 2012 Feb.23(2):245-254. Pubmedid: 22101452.
  • van der Kooi K, Glass LF, Messina JL, Trimble JS. Keratosis pilaris-like eruption observed during the experimental PLX 4032 studies. J Am Acad Dermatol. 2012 Dec.67(6):e286-e287. Pubmedid: 23158643.
  • Lien MH, Fenske NA, Glass LF. Advances in the Chemoprevention of Non-melanoma Skin Cancer in High-Risk Organ Transplant Recipients. Semin Oncol. 2012 Apr.39(2):134-138. Pubmedid: 22484184.
  • Belloni B, Johansen N, Glass LF, Dummer R. Recent advances in the management of cutaneous lymphomas. Semin Oncol. 2012 Apr.39(2):150-162. Pubmedid: 22484187.
  • Glass LF, Deconti RC, Sondak VK. Introduction: advanced cutaneous malignancies. Semin Oncol. 2012 Apr.39(2):132-133. Pubmedid: 22484183.
  • Casper DJ, Glass LF, Shenefelt PD. An unusually large eccrine poroma: a case report and review of the literature. Cutis. 2011 Nov.88(5):227-229. Pubmedid: 22272484.
  • Etzkorn JR, Cherpelis BS, Glass LF. Mohs surgery for melanoma: rationale, advances and possibilities. Expert Rev Anticanc. 2011 Jul.11(7):1043-1054. Pubmedid: 21806328.
  • Naghashpour M, Setoodeh R, Moscinski L, Bergier G, McCardle T, Glass F, Sokol L. Nonnecrobiotic necrobiotic xanthogranuloma as an initial manifestation of paraproteinemia and small lymphocytic lymphoma in a patient with Sjögren syndrome. Am J Dermatopathxxx. 2011 Dec.33(8):855-857. Pubmedid: 22042261.
  • Black WH, Thareja SK, Blake BP, Chen R, Cherpelis BS, Glass LF. Distinction of melanoma in situ from solar lentigo on sun-damaged skin using morphometrics and MITF immunohistochemistry. Am J Dermatopathxxx. 2011 Aug.33(6):573-578. Pubmedid: 21697700.
  • Casper DJ, Ross KI, Messina JL, Sondak VK, Bodden CN, McCardle TW, Frank Glass L. Useof anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma. Am J Dermatopathxxx. 2010 Oct.32(7):650-654. Pubmedid: 20559123.
  • Glass LF, Raziano RM, Clark GS, Higgins HW, Ladd S, Lien MH, Chen R, Cherpelis BS. Rapid frozen section immunostaining of melanocytes by microphthalmia-associated transcription factor. Am J Dermatopathxxx. 2010 Jun.32(4):319-325. Pubmedid: 20514666.
  • Cherpelis BS, Glass LF, Ladd S, Fenske NA. Mohs surgery for melanoma in situ: how we do it. J Drugs Dermatol. 2010 Jul.9(7):786-788. Pubmedid: 20677533.
  • Pothiawala SZ, Baldwin BT, Cherpelis BS, Glass LF, Fenske NA. The role of maintenance phototherapy in cutaneous T-cell lymphoma. J Drugs Dermatol. 2010 Jul.9(7):800-803. Pubmedid: 20677536.
  • Stranahan DR, Cherpelis BS, Fenske NA, Glass LF. Advances in immunostains used in Mohs surgery. J Drugs Dermatol. 2010 Jul.9(7):760-763. Pubmedid: 20677529.
  • Marquez C, Bair SM, Smithberger E, Cherpelis BS, Glass LF. Systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients. J Drugs Dermatol. 2010 Jul.9(7):753-758. Pubmedid: 20677528.
  • Messina J, Möller MG, Sondak VK, Glass FL, Cruse CW. The contoured staged marginal and central surgical excision technique with en face histopathological analysis: useful additions in the armamentarium for treating and diagnosing melanoma in situ. Ann Surg Oncol. 2009 Sep.16(9):2654-2655. Pubmedid: 19588203.
  • Shetty A, Marcum CB, Glass LF, Carter JD. Successful treatment of pemphigus vulgaris with etanercept in four patients. J Drugs Dermatol. 2009 Oct.8(10):940-943. Pubmedid: 19852124.
  • Miller SJ, Alam M, Andersen J, Berg D, Bichakjian CK, Bowen G, Cheney RT, Glass LF, Grekin RC, Hallahan DE, Kessinger A, Lee NY, Liegeois N, Lydiatt DD, Michalski J, Morrison WH, Nehal KS, Nelson KC, Nghiem P, Olencki T, Oseroff AR, Perlis CS, Rosenberg EW, Shaha AR, Urist MM, Wang LC. Merkel cell carcinoma. J Natl Compr Canc Ne. 2009 Mar.7(3):322-332. Pubmedid: 19401064. Pmcid: PMC9444710.
  • Möller MG, Pappas-Politis E, Zager JS, Santiago LA, Yu D, Prakash A, Kinal A, Clark GS, Zhu W, Puleo CA, Glass LF, Messina JL, Sondak VK, Cruse CW. Surgical management of melanoma-in-situ using a staged marginal and central excision technique. Ann Surg Oncol. 2009 Jun.16(6):1526-1536. Pubmedid: 19050971.
  • Raziano RM, Clark GS, Cherpelis BS, Sondak VK, Cruse CW, Fenske NA, Glass LF. Staged margin control techniques for surgical excision of lentigo maligna. G Ital Dermatol Venereol. 2009 Jun.144(3):259-270. Pubmedid: 19528907.
  • Stranahan D, Cherpelis BS, Glass LF, Ladd S, Fenske NA. Immunohistochemical stains in Mohs surgery: a review. Dermatol Surg. 2009 Jul.35(7):1023-1034. Pubmedid: 19397647.
  • Cherpelis BS, Turner L, Ladd S, Glass LF, Fenske NA. Innovative 19-minute rapid cytokeratin immunostaining of nonmelanoma skin cancer in Mohs micrographic surgery. Dermatol Surg. 2009 Jul.35(7):1050-1056. Pubmedid: 19469800.
  • Santillan AA, Cherpelis BS, Glass LF, Sondak VK. Management of familial melanoma and nonmelanoma skin cancer syndromes. Surg Oncol Clin N Am. 2009 Jan.18(1):73-98, viii. Pubmedid: 19056043.
  • Marquez CB, Smithberger EE, Bair SM, Wenham RM, Fenske NA, Glass LF, Cherpelis BS. Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene. Cancer Control. 2009 Jan.16(1):66-69. Pubmedid: 19078932.
  • Cherpelis BS, Moore R, Ladd S, Chen R, Glass LF. Comparison of MART-1 frozen sections to permanent sections using a rapid 19-minute protocol. Dermatol Surg. 2009 Feb.35(2):207-213. Pubmedid: 19215257.
  • Rollison D, Pawlita M, Giuliano A, Iannacone M, Sondak V, Messina J, Cruse C, Fenske N, Glass L, Kienstra M, Michael K, Waterboer T, Gheit T, Tommasino M. Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding nonmelanoma skin cancers. Int J Cancer. 2008 Nov.123(10):2337-2342. Pubmedid: 18729188.
  • Clark G, Pappas-Politis E, Cherpelis B, Messina J, Moller M, Cruse C, Glass L. Surgical management of melanoma in situ on chronically sun-damaged skin. Cancer Control. 2008 Jul.15(3):216-224. Pubmedid: 18596673.
  • Patrick R, Corey S, Glass L. The use of sequential serial sectioning of thin melanomas in determining maximum Breslow depth. J Am Acad Dermatol. 2007 Nov.57:S127-S128. Pubmedid: 17938027.
  • Shistik G, Prakash A, Fenske N, Glass L. Treatment of locally metastatic melanoma: a novel approach. J Drugs Dermatol. 2007 Aug.6(8):830-832. Pubmedid: 17763615.
  • Keehn C, Belongie I, Shistik G, Fenske N, Glass L. The diagnosis, staging, and treatment options for mycosis fungoides. Cancer Control. 2007 Apr.14(2):102-111. Pubmedid: 17387295.
  • Puleo C, Messina J, Riker A, Glass L, Nelson C, Cruse C, Johnson T, Sondak V. Sentinel node biopsy for thin melanomas: which patients should be considered?. Cancer Control. 2005 Oct.12(4):230-235. Pubmedid: 16258494.
  • Bickle K, Glass L, Messina J, Fenske N, Siegrist K. Merkel cell carcinoma: a clinical, histopathologic, and immunohistochemical review. Semin Cutan Med Surg. 2004 Mar.23(1):46-53. Pubmedid: 15095915.
  • Kane C, Keehn C, Smithberger E, Glass L. Histopathology of cutaneous squamous cell carcinoma and its variants. Semin Cutan Med Surg. 2004.23(1):54-61. Pubmedid: 15095916.
  • Kolanko E, Bickle K, Keehn C, Glass L. Subepidermal blistering disorders: a clinical and histopathologic review. Semin Cutan Med Surg. 2004.23(1):10-18. Pubmedid: 15095911.
  • Perrott R, Glass L, Reintgen D, Fenske N. Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma. J Am Acad Dermatol. 2003 Oct.49(4):567-588. Pubmedid: 14512901.
  • Cherpelis B, Haddad F, Messina J, Cantor A, Fitzmorris K, Reintgen D, Fenske N, Glass L. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas. J Am Acad Dermatol. 2001 May.44(5):762-766. Pubmedid: 11312421.
  • McMasters K, Reintgen D, Ross M, Gershenwald J, Edwards M, Sober A, Fenske N, Glass L, Balch C. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol. 2001 Jun.19(11):2851-2855. Pubmedid: 11387357.
  • Rinker MH, Fenske NA, Scalf LA, Glass LF. Histologic variants of squamous cell carcinoma of the skin. Cancer Control. 2001 Jul.8(4):354-363. Pubmedid: 11483889.
  • Shivers S, Li W, Stall A, Stafford M, Messina J, Glass L, Reintgen D. The clinical relevance of molecular staging for melanoma. Recent Results Cancer Res. 2001.158:187-199. Pubmedid: 11092046.
  • Li W, Stall A, Shivers S, Lin J, Haddad F, Messina J, Glass F, Lyman G, Reintgen D. Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg. 2000 Jun.231(6):795-803. Pubmedid: 10816622. Pmcid: PMC1421068.
  • Smith D, Messina J, Perrott R, Berman C, Reintgen D, Cruse C, Glass F, DeConti R, Trotti A, Fenske N. Clinical approach to neuroendocrine carcinoma of the skin (Merkel cell carcinoma). Cancer Control. 2000 Jan.7(1):72-83. Pubmedid: 10740663.
  • Byrd-Gloster A, Khoor A, Glass L, Messina J, Whitsett J, LivingstonSK, Cagle P. Differential expression of thyroid transcription factor 1 in small cell lung carcinoma and Merkel cell tumor. Hum Pathol. 2000 Jan.31(1):58-62. Pubmedid: 10665914.
  • Fairbee S, Morgan M, Tannenbaum M, Glass L. Fibromucinous T-cell lymphoma: a new clinicopathologic variant of mycosis fungoides?. Am J Dermatopathxxx. 2000.22(6):515-518. Pubmedid: 11190443.
  • Pu LL, Cruse CW, Wells KE, Cantor A, Glass LF, Messina JL, Reintgen DS. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma of the lower extremity. Plast Reconstr Surg. 1999 Sep.104(4):964-969. Pubmedid: 10654734.
  • Barnhill RL, Argenyi ZB, From L, Glass LF, Maize JC, Mihm MC, Rabkin MS, Ronan SG, White WL, Piepkorn M. Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol. 1999 May.30(5):513-520. Pubmedid: 10333219.
  • Haddad FF, Stall A, Messina J, Brobeil A, Ramnath E, Glass LF, Cruse CW, Berman CG, Reintgen DS. The progression of melanoma nodal metastasis is dependent on tumor thickness of the primary lesion. Ann Surg Oncol. 1999 Mar.6(2):144-149. Pubmedid: 10082038.
  • Messina J, Glass L, Cruse C, Berman C, Ku N, Reintgen D. Pathologic examination of the sentinel lymph node in malignant melanoma. Am J Surg Pathol. 1999 Jun.23(6):686-690. Pubmedid: 10366151.
  • Brobeil A, Cruse CW, Messina JL, Glass LF, Haddad FF, Berman CG, Marshburn J, Reintgen DS. Cost analysis of sentinel lymph node biopsy as an alternative to elective lymph node dissection in patients with malignant melanoma. Surg Oncol Clin N Am. 1999 Jul.8(3):435-45, viii. Pubmedid: 10448688.
  • Goscin C, Glass LF, Messina JL. Pathologic examination of the sentinel lymph node in melanoma. Surg Oncol Clin N Am. 1999 Jul.8(3):427-34, viii. Pubmedid: 10448687.
  • Glass L, Cottam J, Reintgen D, Fenske N. Lymphatic mapping and sentinel node biopsy in the management of high-risk melanoma. J Am Acad Dermatol. 1998 Oct.39(4 Pt 1):603-610. Pubmedid: 9777768.
  • Shivers S, Wang X, Li W, Joseph E, Messina J, Glass L, DeConti R, Cruse W, Berman C, Fenske N, Lyman G, Reintgen D. Molecular staging of malignant melanoma: correlation with clinical outcome. Jama. 1998 Oct.280(16):1410-1415. Pubmedid: 9801000.
  • Mir L, Glass L, Sersa G, Teissie J, Domenge C, Miklavcic D, Jaroszeski M, Orlowski S, Reintgen D, Rudolf Z, Belehradek M, Gilbert R, Rols M, Belehradek J, Bachaud J, DeConti R, Stabuc B, Cemazar M, Coninx P, Heller R. Effective treatment of cutaneous and subcutaneous malignant tumors by electrochemotherapy. Br J Cancer. 1998 Jun.77(12):2336-2342. Pubmedid: 9649155.
  • Harvey D, Fenske N, Glass L. Rosaceous lymphedema: a rare variant of a common disorder. Cutis. 1998 Jun.61(6):321-324. Pubmedid: 9640553.
  • Heller R, Jaroszeski MJ, Reintgen DS, Puleo CA, DeConti RC, Gilbert RA, Glass LF. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer. 1998 Jul.83(1):148-157. Pubmedid: 9655305.
  • Glass L, Keller K, Messina J, Dalton J, Yag-Howard C, Fenske N. Cutaneous T-cell Lymphoma. Cancer Control. 1998 Jan.5(1):11-18. Pubmedid: 10761012.
  • Glass LF, Jaroszeski M, Gilbert R, Reintgen DS, Heller R. Intralesional bleomycin-mediated electrochemotherapy in 20 patients with basal cell carcinoma. J Am Acad Dermatol. 1997 Oct.37(4):596-599. Pubmedid: 9344200 .
  • Keller KL, Fenske NA, Glass LF. Cancer of the skin in the older patient. Clin Geriatr Med. 1997 May.13(2):339-361. Pubmedid: 9115455.
  • Kamath D, Rapaport D, DeConti R, Cruse C, Wells K, Glass L, Messina J, Fenske N, Brobeil A, Berman C, Puleo C, Reintgen D. Redefining cutaneous lymphatic flow: the necessity of preoperative lymphoscintigraphy in the management of malignant melanoma. J Fla Med Assoc. 1997 Mar.84(3):182-187. Pubmedid: 9143170.
  • Reintgen D, Albertini J, Milliotes G, Marshburn J, Cruse C, Rapaport D, Berman C, Glass L, Fenske N, Einstein, Jr. A, Lyman G. Investment in new technology research can save future health care dollars. J Fla Med Assoc. 1997 Mar.84(3):175-181. Pubmedid: 9143169.
  • Le A, Fenske N, Glass L, Messina J. Malignant melanoma: differential diagnosis of pigmented lesions. J Fla Med Assoc. 1997 Mar.84(3):166-174. Pubmedid: 9143168.
  • Kamath D, Cantor A, Glass L, Fenske N, Cruse C, Wells K, Rapaport D, DeConti R, Messina J, Reintgen D. Florida's undeclared epidemic: malignant melanoma. J Fla Med Assoc. 1997 Mar.84(3):161-165. Pubmedid: 9143167.
  • Brobeil A, Kamath D, Cruse CW, Rapaport DP, Wells KE, Shons AR, Messina JL, Glass LF, Berman CG, Puleo CA, Reintgen DS. The clinical relevance of sentinel lymph nodes identified with radiolymphoscintigraphy. J Fla Med Assoc. 1997 Mar.84(3):157-160. Pubmedid: 9143166.
  • Messina JL, Glass LF. Pathologic examination of the sentinel lymph node. J Fla Med Assoc. 1997 Mar.84(3):153-156. Pubmedid: 9143165.
  • Messina J, Reintgen D, Cruse C, Rapaport D, Berman C, Fenske N, Glass L. Selective lymphadenectomy in patients with Merkel cell (cutaneous neuroendocrine) carcinoma. Ann Surg Oncol. 1997 Jul.4(5):389-395. Pubmedid: 9259965.
  • Milotes G, Lyman G, Cruse C, Puleo C, Albertini J, Rapaport D, Glass L, Fenske N, Soriano T, Cuny C, VanVoorhis N, Reintgen D. Evaluation of new putative tumor markers for melanoma. Ann Surg Oncol. 1996 Nov.3(6):558-563. Pubmedid: 8915488.
  • Glass LF, Fotopoulos T, Messina J. A generalized cutaneous reaction induced by granulocyte colony-stimulating factor. J Am Acad Dermatol. 1996 Mar.34(3):455-459. Pubmedid: 8609259.
  • Heller R, Jaroszeski M, Glass L, Messina J, Rapaport D, DeConti R, Fenske N, Gilbert R, Mir L, Reintgen D. Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer. 1996 Mar.77(5):964-971. Pubmedid: 8608491 .
  • Meliotis G, Albertini J, Berman C, Heller R, Messina J, Glass L, Cruse C, Rapaport D, Puleo C, Fenske N, Petsofglov C, DeConti R, Lyman G. The tumor biology of melanoma nodal metastases. Am Surg. 1996 Jan.62(1):81-88. Pubmedid: 8540654.
  • Albertini J, Cruse C, Rapaport D, Wells K, DeConti R, Berman C, Jared K, Messina J, Lyman G, Glass L, Fenske N, Reintgen D. Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg. 1996 Feb.223(2):217-224. Pubmedid: 8597518. Pmcid: PMC1235100.
  • Glass LF, Messina JL, Cruse W, Wells K, Rapaport D, Miliotes G, Berman C, Reintgen D, Fenske NA. The use of intraoperative radiolymphoscintigraphy for sentinel node biopsy in patients with malignant melanoma. Dermatol Surg. 1996 Aug.22(8):715-720. Pubmedid: 8780765.
  • Glass L, Albertini J, Fenske N, Reintgen D. Lymphatic mapping and selective lymphadenectomy in patients with cutaneous melanoma. Curr Opin Hematol. 1996.3:63-70.
  • Nixon D, Greene J, Sandin R, Fenske N, Glass L. Empirical treatment of subcutaneous phaeohyphomycosis with itraconazole. Infect Med. 1996.13(6):481+-481+.
  • Heller R, Jaroszeski M, Glass L, Messina J, Rapaport D, DeConti R, Fenske N, Gilbert R, Mir L, Reintgen D. Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer. 1996.77(5):964-971. Pubmedid: 8608491.
  • Glass LF, DeGregoria L, Fenske NA, Jaroszeski M, Perrott R, Harvey DT, Reintgen DS, Heller R. Bleomycin-mediated electrochemotherapy of basal cell carcinoma. J Am Acad Dermatol. 1996.34(1):82-86. Pubmedid: 8543699.
  • Glass L, Pepine M, Fenske N, Jaroszeski M, Reintgen D, Heller R. Bleomycin-mediated electrochemotherapy of metastatic melanoma. Arch Dermatol. 1996.132:1353-1357. Pubmedid: 8915314.
  • Glass L, Fenske N, Messina J, Cruse C, Rapaport D, Berman C, Puleo C, Heller R, Miliotes G, Albertini J, Reintgen D. The role of selective lymphadenectomy in the management of patients with malignant melanomoa. Dermatol Surg. 1996.21:979-983.
  • Nixon D, Greene J, Sandin R, Fenske N, Glass L. Empirical treatment of subcutaneous phaeohyphomycosis with itraconazole. Infect Med. 1996.13(6):481-481.
  • Reintgen D, Albertini J, Berman C, Cruse C, Fenske N, Glass L, Puleo C, Wang X, Wells K, Rapaport D, DeConti R, Messina J, Heller R. Accurate Nodal Staging of Malignant Melanoma. Cancer Control. 1995 Oct.2(5):405-414. Pubmedid: 10862181.
  • Smith J, Hogan D, Glass L, Fenske N. Multiple collagenomas in a patient with Down syndrome. J Am Acad Dermatol. 1995 Nov.33(5 Pt 1):835-837. Pubmedid: 7593790.
  • Glass LF, Fenske NA, Messina JL, Cruse CW, Rapaport DP, Berman C, Puleo CA, Heller R, Miliotes G, Albertini J. The role of selective lymphadenectomy in the management of patients with malignant melanoma. Dermatol Surg. 1995 Nov.21(11):979-983. Pubmedid: 7582838.
  • Dominguez E, Greene J, Sandin R, DeGregorio R, Glass L. Sweet Syndrome and Leukemia Cutis in the Same Patient: A Case Report and Review. Cancer Control. 1995 Jul.2(4):343-346. Pubmedid: 10862176.
  • Haag M, Glass L, Fenske N. Merkel cell carcinoma. Diagnosis and treatment. Dermatol Surg. 1995 Aug.21(8):669-683. Pubmedid: 7633811.
  • Chaney J, Guffey, Stevens G, Schroer K, Fenske N, Reintgen D, Glass L. Immunohistochemical assessment of tumor vascularity in recurrent Clark II melanomas using antibody to type IV collagen. J Cutan Pathol. 1995 Apr.22(2):122-127. Pubmedid: 7560343.
  • Vesper J, Messina J, Glass L, Fenske N. Profound proliferating pearly penile papules. Int J Dermatol. 1995.34(6):425-426. Pubmedid: 7657443.
  • DeGregorie R, Fenske N, Glass L. Granulomatous slack skin: a possible precursor of Hodgkin's disease. J Am Acad Dermatol. 1995.33(6):1044-1047. Pubmedid: 7490351.
  • Albers SE, Glass LF, Fenske NA. Lichen planus subtropicus: direct immunofluorescence findings and therapeutic response to hydroxychloroquine. Int J Dermatol. 1994 Sep.33(9):645-647. Pubmedid: 8002164.
  • Reintgen D, Cruse CW, Wells K, Berman C, Fenske N, Glass F, Schroer K, Heller R, Ross M, Lyman G. The orderly progression of melanoma nodal metastases. Ann Surg. 1994 Dec.220(6):759-767. Pubmedid: 7986143. Pmcid: PMC1234478.
  • Reintgen D, Cruse C, Wells K, Berman C, Fenske N, Glass L, Schroer K, Heller R, Ross M, Lyman G, Cox C, Rapaport D, Seigler H, Balch C. The orderly progression of melanoma nodal metastases. Ann Surg. 1994.220(6):759-767.
  • Albers S, Fenske N, Glass L, Brozena S, Szakacs J. Atypical B(2)-microglobulin amyloidosis following short-term hemodialysis. Am J Dermatopathxxx. 1994.16:179-184.
  • Calderone D, Glass L, Seleznick M, Fenske N. Eccrine angiomatous hamartoma. J Dermatol Surg Oncol. 1994.20:837-838.
  • Austin P, Cruse C, Lyman G, Schroer K, Glass L, Reintgen D. Age as a prognostic factor in the malignant melanoma population. Ann Surg Oncol. 1994.1(6):487-494.
  • Wang X, Heller R, Cruse C, VanVoorhis N, Glass L, Fenske N, Berman C, Leo-Messina J, Rapaport D, Wells K, DeConti R, Moscinski L, Stankard C, Puleo C, Reintgen D. Detection of submicroscopic lymph node metasases with polymerase chain reaction in patients with malignant melanoma. Ann Surg. 1994.220:768-774.
  • Glass LF, Guffey JM, Schroer KR, Reintgen D. Histopathologic study of recurrent Clark level II melanomas. Semin Surg Oncol. 1993 May.9(3):202-207. Pubmedid: 8516604.
  • Glass L, Guffey J, Schroer K, Reintgen D. A histopathologic study of recurrent Clark level II melanoma. Semin Surg Oncol. 1993.9:202-207.
  • Reintgen D, Cruse C, Schroer K, Glass L, Saba H, Puleo C, King J, Berman C, Hannon L, Cox C. Computer database for melanoma: a clinical management and research tool to ensure continuous quality assessment. Semin Surg Oncol. 1993.9:208-214.
  • Albers S, Fenske N, Glass L. Erythema gyratum repens: direct immunofluorenscence microscopic findings. J Am Acad Dermatol. 1993.29:493-494.
  • Reintgen D, Cruse C, Wells K, Stankard C, Saba H, Schroer K, Cox C, Berman C, Glass L, Alvarez L, Brozena S, Fenske N, Fabri P. The effectiveness of skin cancer screening and continuing education programs toward increasing the survival of patients with malignant melanoma. Surg Oncol. 1992.1:379-384.
  • Albers S, Brozena S, Glass L, Fenske N. Alkaptonuria and ochronosis: case report and review. J Am Acad Dermatol. 1992.27:609-614.
  • Glass LF, Maize JC. Morsicatio buccarum et labiorum (excessive cheek and lip biting). Am J Dermatopathxxx. 1991 Jun.13(3):271-274. Pubmedid: 1867357.
  • Glass LF, Berman B, Laub D. Treatment of perifolliculitis capitis abscedens et suffodiens with the carbon dioxide laser. J Dermatol Surg Oncol. 1989 Jun.15(6):673-676. Pubmedid: 2723230.
  • Glass LF, Huntley AC. Allergic contact dermatitis. Common allergens. Clin Rev Allergy. 1989.7(4):381-398. Pubmedid: 2691042.
  • SHEA PC, GLASS LF, REID WA, HARLAND A. Anastomosis of common and internal carotid arteries following excision of mycotic aneurysm. Surgery. 1955 May.37(5):829-832. Pubmedid: 14373301.
  • Shistik G, Scalf L, Fenske N, Glass L. Follicular mycosis fungoides: successful treatment with oral bexarotene. J Drugs Dermatol. 3(3):301-304. Pubmedid: 15176165.
  • Riker A, Glass F, Perez I, Cruse C, Messina J, Sondak V. Cutaneous melanoma: methods of biopsy and definitive surgical excision. Dermatol Ther. 18(5):387-393. Pubmedid: 16297013.
  • Kudchadkar RR, Smalley KS, Glass LF, Trimble JS, Sondak VK. Targeted therapy in melanoma. Clin Dermatol. 31(2):200-208. Pubmedid: 23438383.

Patient Comments
Overall Satisfaction
4.8

272 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments